Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Paclitaxel in PD-(L)1 Resistant Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT06118645Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by China Medical University. Primary endpoint: 6-month Progression-Free Survival. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT06118645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118645.